Abstract
PURPOSE: Metastatic involvement of the liver frequently determines the evolution of the clinical picture in colorectal cancer patients. We examined the efficacy and toxicity of chemoembolization in this setting, identifying prognostic factors to define patients most likely to benefit from the procedure. METHODS: Forty patients underwent chemoembolization of metastatic liver lesions from colorectal carcinoma. Selective angiography of the hepatic artery was performed to identify the feeding vessels of the metastatic lesions. The injected chemoemulsion consisted of 1,000 mg of 5-fluorouracil, 10 mg of mitomycin C, and 10 ml of ethiodized oil in a total volume of 30 ml. Gelfoam embolization then followed, until stagnation of blood flow was achieved. Patients were evaluated for response, overall survival, and toxicities. RESULTS: Overall median survival from date of first chemoembolization was ten months. Factors that predicted a longer median survival included favorable performance status (24 months), serum alkaline phosphatase and lactate dehydrogenase levels less than three times normal (24 and 12 months, respectively), and metastatic disease confined to the liver (14 months). Most patients tolerated the procedure well. The most common side effects were transient fevers, abdominal pain, and fatigue. Three patients died within one month from the procedure. CONCLUSION: This study suggests that chemoembolization of hepatic metastases in colorectal cancer should be further evaluated; it may be beneficial in patients who have failed systemic chemotherapy, have a good performance status, and have metastatic disease confined to the liver.
Similar content being viewed by others
References
Weiss L, Grundmann E, Torhorst J,et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986;150:195–203.
Wood CB, Gillis CR, Blumgart LH. A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 1976;2:285–8.
Hohn DC, Stagg RJ, Friedman MA,et al. A randomized trial of continuous intravenousvs. hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989;7:1646–54.
Kemeny N, Cohen A, Seiter K,et al. Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustinevs. floxuridine alone in previously treated patients with liver metastases from colorectal cancer. J Clin Oncol 1993;11:330–5.
Rougier P, Laplance A, Hugier M,et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992;10:1112–8.
Wagman LD, Kemeny MM, Leong L,et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990;8:1885–93.
Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896–903.
Colucci G, Maiello E, Giuliani F, Cifarelli CA, Giotta F. Carboplatin and etoposide in previously treated colorectal cancer patients. Tumori 1995;81:36–8.
Stuart K, Posner M, Campbell K, Huberman M. Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma. Am J Clin Oncol 1995;18:300–2.
Conti JA, Kemeny NE, Saltz LB, Andre AM, Grossano DD, Bertino JR. Continuous infusion fluorouracil/ leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. Cancer 1995;75:769–74.
Rothenberg ML, Eckardt JR, Kuhn JG,et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128–35.
Hughes K, Scheele J, Sugarbaker PH. Surgery for colorectal cancer metastatic to the liver. Surg Clin North Am 1989;69:339–59.
Cady B, Stone M. The role of surgical resection of liver metastases in colorectal carcinoma. Semin Oncol 1991;18:399–406.
Patt YZ. Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: the controversy continues. J Clin Oncol 1993;11:815–9.
Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996;88:252–8.
Lorenz M, Herrmann G, Kirkowa-Reimann M,et al. Temporary chemoembolization of colorectal liver metastases with degradable starch microspheres. Eur J Surg Oncol 1989;15:453–62.
Meakem TJ, Unger EC, Pond GD, Modiano MR, Alberts DR. CT findings after hepatic chemoembolization. J Comput Assist Tomogr 1992;16:916–20.
Kameyama M, Imaoka S, Fukuda I,et al. Delayed washout of intratumor blood flow is associated with good response to intraarterial chemoembolization for liver metastases of colorectal cancer. Surgery 1993;114:97–101.
Hunt TM, Flowerdew AD, Birch SJ, Williams JD, Mullee MA, Taylor I. Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases. Br J Surg 1990;77:779–82.
Lang EK, Brown CL. Colorectal metastases to the liver: Selective chemoembolization. Radiology 1993;189:417–22.
Martinelli DJ, Wadler S, Bakal CW,et al. Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer 1994;74:1706–12.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81.
Borner M, Castiglione M, Triller J,et al. Considerable side-effects of chemoembolization for colorectal carcinoma metastatic to the liver. Ann Oncol 1992;3:113–5.
Stuart K, Posner M, Huberman M, Steele G, Stokes K. Chemoembolizationfor hepatic metastases from colorectal carcinoma [abstract]. Proc Am Soc Clin Oncol 1994;13:227.
Kemeny N, Niedzwiecki D, Shurgot B, Oderman P. Prognostic variables in patients with hepatic metastases from colorectal cancer. Cancer 1989;63:742–7.
Goslin R, Steele G Jr, Zamcheck N, Mayer R, MacIntyre J. Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum 1982;25:749–54.
Author information
Authors and Affiliations
About this article
Cite this article
Sanz-Altamira, P.M., Spence, L.D., Huberman, M.S. et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma. Dis Colon Rectum 40, 770–775 (1997). https://doi.org/10.1007/BF02055430
Issue Date:
DOI: https://doi.org/10.1007/BF02055430